Semax

Semax (ACTH 4-10 fragment analog)

Russian neuroprotective peptide · ACTH 4-10 derivative

FDA Status

Not FDA-approved · Approved in Russia

Class

Heptapeptide · ACTH (4-10) Pro-Gly-Pro extension

Sequence

Met-Glu-His-Phe-Pro-Gly-Pro

Half-life

~30-60 min

Mechanism of action

• BDNF and NGF (nerve growth factor) upregulation
• Modulates dopaminergic and serotonergic systems
• Neuroprotection via anti-inflammatory pathways
• Improves cerebral blood flow

Research areas

• Acute ischemic stroke (Russian standard of care)
• Cognitive impairment and ADHD
• Optic nerve atrophy
• Memory consolidation studies

Evidence and clinical data

Approved in Russia for stroke recovery since 1990s. Western literature is sparse but growing. Phase II equivalent data exists for stroke.

Safety profile

Well-tolerated in Russian post-market data. Intranasal route minimizes systemic exposure. Limited Western pharmacovigilance.